Publications by authors named "Debra Niehoff"
Frontotemporal degeneration (FTD) is an umbrella term encompassing a range of rare neurodegenerative disorders that cause progressive declines in cognition, behavior, and personality. Hearing directly from individuals living with FTD and their care partners is critical in optimizing care, identifying meaningful clinical trial endpoints, and improving research recruitment and retention. The current paper presents a subset of data from the FTD Insights Survey, chronicling the diagnostic journey, symptoms, and the impact of FTD on distress, quality of life, and independence, in the mild to moderate stages of the disease.
View Article and Find Full Text PDFArticle Synopsis
- Drug development for Alzheimer’s and other neurodegenerative dementias has faced many trials that failed to demonstrate the effectiveness of new drugs.
- Exploratory clinical trials, which are shorter and smaller than traditional trials, aim to assess drug effects and can help determine whether to continue or terminate a drug's development.
- Organizations like the Alzheimer’s Drug Discovery Foundation are working to create guidelines that improve the design and efficiency of these exploratory trials, potentially leading to faster and more cost-effective drug development.
Introduction: Frontotemporal lobar degeneration (FTLD) is the most common form of dementia for those under 60 years of age. Increasing numbers of therapeutics targeting FTLD syndromes are being developed.
Methods: In March 2018, the Association for Frontotemporal Degeneration convened the Frontotemporal Degeneration Study Group meeting in Washington, DC, to discuss advances in the clinical science of FTLD.